Adamis Pharmaceuticals Starts Prostate Cancer Drug Trial

Adamis Pharmaceuticals announced that it enrolled the first patient in its Phase I/IIa clinical prostate study. In the study, patients will be assessed for toxicity, biochemical, radiographic and clinical responses.

San Diego-based Adamis Pharmaceuticals has enrolled the first patient in its Phase I/IIa clinical prostate study of APC-100 as a treatment for men with castration-resistant prostate cancer.

APC-100 is an orally available anti-androgenic or anti-inflammatory, signal transduction inhibitor drug, shown to have higher therapeutic activity than the current marketed standard of care anti-androgens.

Preclinical studies confirmed the use of APC-100 for the treatment of prostate cancer.

In the Phase I/IIa study, each patient will be assessed for toxicity, biochemical, radiographic and clinical responses.

Adamis Pharma